Iovance Biotherapeutics stock fell 6% due to analyst recommendation downgrade and disappointing earnings report

From Nasdaq MarketSite: 2025-05-16 18:39:00

Iovance Biotherapeutics (NASDAQ: IOVA) saw its stock drop nearly 6% due to an analyst’s recommendation downgrade, despite a positive day for equities with the S&P 500 rising 0.7%. UBS analyst David Dai changed his recommendation to neutral from buy and lowered the price target from $17 to $2 per share. The downgrade came after the company’s latest quarterly earnings report, where sales of their leading product Amtagvi fell below expectations, signaling a slower commercialization ramp-up and higher drop-out rates, raising concerns about patient selection.

Investors are cautioned about investing in Iovance Biotherapeutics as the company faces slow commercialization, a notable revenue guidance cut, and concerns raised by analyst David Dai. The analyst highlighted flaws in patient selection and a slow ramp-up, making the stock a risky investment at the moment. The Motley Fool Stock Advisor team did not include Iovance Biotherapeutics in their list of 10 best stocks to buy now, citing better potential returns from other stocks on the list.

Disclaimer: Eric Volkman has no position in any stocks mentioned, but The Motley Fool has positions in and recommends Iovance Biotherapeutics. The views expressed are solely those of the author and not of Nasdaq, Inc.



Read more at Nasdaq MarketSite: Why Iovance Biotherapeutics Tumbled by Nearly 6% Today